Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 20/20 | 0.72 |
| ▸ | EGFR | P00533 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.66 |
| ▸ | PRKACA | P17612 | 2/20 | 0.65 |
| ▸ | PRKACG | P22612 | 2/20 | 0.65 |
| ▸ | PRKACB | P22694 | 2/20 | 0.65 |
| ▸ | IKBKB | O14920 | 1/20 | 0.65 |
| ▸ | MMP3 | P08254 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | PRKCA | P17252 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27707417 | 0.94 | MAP3K8 (0.66) | MAP3K8EGFRCYP3A4MAPKAPK2PRKACA | |
| SCHEMBL4961615 | 0.85 | MAP3K8 (0.82) | MAP3K8EGFRMAPKAPK2SRC | |
| SCHEMBL27707678 | 0.84 | MAP3K8 (0.75) | MAP3K8EGFRCYP3A4MAPKAPK2PRKACA | |
| SCHEMBL4964129 | 0.83 | MAP3K8 (0.75) | MAP3K8EGFRCYP3A4MAPKAPK2PRKACA | |
| SCHEMBL27707380 | 0.83 | MAP3K8 (0.78) | MAP3K8EGFRCYP3A4MAPKAPK2PRKACA | |
| SCHEMBL4960478 | 0.83 | MAP3K8 (0.88) | MAP3K8EGFRCYP3A4MAPKAPK2RPS6KB1 | |
| SCHEMBL6071940 | 0.82 | MAP3K8 (1.00) | MAP3K8EGFRMAPKAPK2SRC | |
| SCHEMBL4964645 | 0.82 | MAP3K8 (0.81) | MAP3K8EGFRCYP3A4MAPKAPK2PRKACA | |
| SCHEMBL27728235 | 0.81 | MAP3K8 (0.84) | MAP3K8 | |
| SCHEMBL6071382 | 0.81 | MAP3K8 (0.69) | MAP3K8EGFRCYP3A4MAPKAPK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101223143-A | 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | MAP3K8 84/4885EGFR 4122/4885CYP3A4 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.